snoofek/iStock via Getty Images The performance of mid-cap medical device company Enovis (NYSE:ENOV) is getting harder and harder for me to understand. As I’ve said in past articles, I’ve never really loved this business, and I’ve found some of management’s projections to be overly optimistic, but I do think there is a solid orthopedic device business here, and I find the stock’s behavior relative to underlying performance to be stranger and stranger. Since my last update, Enovis shares are down around  ...